TY - JOUR
T1 - Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease
T2 - A cross-sectional study in North America
AU - Ladapo, Joseph A.
AU - Coles, Adrian
AU - Dolor, Rowena J.
AU - Mark, Daniel B.
AU - Cooper, Lawton
AU - Lee, Kerry L.
AU - Goldberg, Jonathan
AU - Shapiro, Michael D.
AU - Hoffmann, Udo
AU - Douglas, Pamela S.
N1 - Funding Information:
Funding The PROMISE trial was funded by National Heart, Lung, and Blood Institute grants R01 HL098237, R01 HL098236, R01 HL098305 and R01 HL098235. Dr Ladapo’s work is supported by the National Heart, Lung,and Blood Institute (K23 HL116787) and he serves as a consultant to CardioDx, Inc. Dr Douglas has received grant support from HeartFlow and serves on a data and safety monitoring board for General Electric Healthcare; Dr Hoffmann has received grant support from Siemens Healthcare and HeartFlow; Dr Mark has received personal fees from Medtronic, CardioDx and St Jude Medical and grant support from Eli Lilly, Bristol-Myers Squibb, Gilead Sciences, AGA Medical, Merck, Oxygen Biotherapeutics and AstraZeneca. No financial disclosures were reported by the other authors of this paper.
Publisher Copyright:
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Objectives To evaluate potential gaps in preventive medical therapy and healthy lifestyle practices among symptomatic patients with suspected coronary artery disease (CAD) seeing primary care physicians and cardiologists and how gaps vary by sociodemographic characteristics and baseline cardiovascular risk. Design Cross-sectional study assessing potential preventive gaps. Participants 10 003 symptomatic outpatients evaluated by primary care physicians, cardiologists or other specialists for suspected CAD. Setting PROspective Multicenter Imaging Study for Evaluation of Chest Painfrom 2010 to 2014. Measures Primary measures were absence of an antihypertensive, statin or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for renal protection in patients with hypertension, dyslipidaemia or diabetes, respectively, and being sedentary, smoking or being obese. Results Preventive treatment gaps affected 14% of patients with hypertension, 36% of patients with dyslipidaemia and 32% of patients with diabetes. Overall, 49% of patients were sedentary, 18% currently smoked and 48% were obese. Women were significantly more likely to not take a statin for dyslipidaemia and to be sedentary. Patients with lower socioeconomic status were also significantly more likely to not take a statin. Compared with Whites, Blacks were significantly more likely to be obese, while Asians were less likely to smoke or be obese. High-risk patients sometimes experienced larger preventive care gaps than low-risk patients. For patients with dyslipidaemia, the presence of a treatment gap was associated with a higher risk of an adverse event (HR 1.35, 95% CI 1.02 to 1.82). Conclusions Among contemporary, symptomatic patients with suspected CAD, significant gaps exist in preventive care and lifestyle practices, and high-risk patients sometimes had larger gaps. Differences by sex, age, race/ethnicity, socioeconomic status and geography are modest but contribute to disparities and have implications for improving opulation health. For patients with dyslipidaemia, the presence of a treatment gap was associated with a higher risk of an adverse event. Clinical trial registration Clinical Trials.gov identifier NCT01174550.
AB - Objectives To evaluate potential gaps in preventive medical therapy and healthy lifestyle practices among symptomatic patients with suspected coronary artery disease (CAD) seeing primary care physicians and cardiologists and how gaps vary by sociodemographic characteristics and baseline cardiovascular risk. Design Cross-sectional study assessing potential preventive gaps. Participants 10 003 symptomatic outpatients evaluated by primary care physicians, cardiologists or other specialists for suspected CAD. Setting PROspective Multicenter Imaging Study for Evaluation of Chest Painfrom 2010 to 2014. Measures Primary measures were absence of an antihypertensive, statin or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for renal protection in patients with hypertension, dyslipidaemia or diabetes, respectively, and being sedentary, smoking or being obese. Results Preventive treatment gaps affected 14% of patients with hypertension, 36% of patients with dyslipidaemia and 32% of patients with diabetes. Overall, 49% of patients were sedentary, 18% currently smoked and 48% were obese. Women were significantly more likely to not take a statin for dyslipidaemia and to be sedentary. Patients with lower socioeconomic status were also significantly more likely to not take a statin. Compared with Whites, Blacks were significantly more likely to be obese, while Asians were less likely to smoke or be obese. High-risk patients sometimes experienced larger preventive care gaps than low-risk patients. For patients with dyslipidaemia, the presence of a treatment gap was associated with a higher risk of an adverse event (HR 1.35, 95% CI 1.02 to 1.82). Conclusions Among contemporary, symptomatic patients with suspected CAD, significant gaps exist in preventive care and lifestyle practices, and high-risk patients sometimes had larger gaps. Differences by sex, age, race/ethnicity, socioeconomic status and geography are modest but contribute to disparities and have implications for improving opulation health. For patients with dyslipidaemia, the presence of a treatment gap was associated with a higher risk of an adverse event. Clinical trial registration Clinical Trials.gov identifier NCT01174550.
KW - cardiac stress testing
KW - coronary artery disease
KW - coronary computed tomography angiography
KW - health disparities
KW - socioeconomics
UR - http://www.scopus.com/inward/record.url?scp=85030457124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030457124&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2017-016364
DO - 10.1136/bmjopen-2017-016364
M3 - Article
C2 - 28965093
AN - SCOPUS:85030457124
SN - 2044-6055
VL - 7
JO - BMJ Open
JF - BMJ Open
IS - 9
M1 - e016364
ER -